Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.

Der Pathologe - 1 Nov 2021

Hummel Michael, Hegewisch-Becker Susanna, Neumann Jens H L, Vogel Arndt

Abstract excerpt

In the past 25 years, treatment of metastatic colorectal cancer (mCRC) has undergone profound changes. The approval of newer chemotherapeutics such as irinotecan and oxaliplatin was followed in 2005 by the first targeted therapies, for example, monoclonal antibodies directed against the epidermal growth factor receptor (EGFR), as cetuximab and panitumumab, or the angiogenesis inhibitors bevacizumab, ramucirumab,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Mutation

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 34259881
DOI: 10.1007/s00292-021-00946-5
PMCID: PMC8571135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.PMID 34259881Read ↗

[BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].Semantic proximity Read ↗

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.Semantic proximity Read ↗

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerSemantic proximity Read ↗

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.Semantic proximity Read ↗

BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable MutationSemantic proximity Read ↗

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Current and Emerging Biomarkers in Metastatic Colorectal CancerSemantic proximity Read ↗

Molecular Targets for the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.